SCHEMBL12490689

SCHEMBL12490689

Nc1ncc2ccccc2c1C1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
GPR3 P46089 1/20 0.42
ACHE P22303 2/20 0.41
BCHE P06276 1/20 0.41
F12 P00748 1/20 0.41
PLAU P00749 1/20 0.41
NCF1 P14598 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
BACE1 P56817 1/20 0.41
USP7 Q93009 1/20 0.40
CFTR P13569 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GOPC Q9HD26 1/20 0.38
PDPK1 O15530 1/20 0.38
DHFR P00374 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12527287 0.80 GPR3 (0.41) KDM4EGPR3ACHEBCHEHSD17B10
SCHEMBL28301397 0.74 KDM4E (0.50) KDM4EGPR3ACHEF12PLAU
SCHEMBL29127161 0.73 ALDH1A1 (0.45) ACHEBCHEF12PLAUNCF1
SCHEMBL12491150 0.72 PLAU (0.44) KDM4EGPR3ACHEBCHEF12
SCHEMBL7258713 0.71 KDM4E (0.47) KDM4EGPR3ACHEF12PLAU
SCHEMBL15401178 0.71 KDM4E (0.47) KDM4EGPR3ACHEF12PLAU
SCHEMBL558613 0.71 KDM4E (0.47) KDM4EGPR3ACHEF12PLAU
SCHEMBL12490240 0.71 KDM4E (0.47) KDM4EGPR3F12PLAUNCF1
SCHEMBL22758297 0.69 NCF1 (0.44) KDM4EGPR3ACHEBCHENCF1
SCHEMBL11331611 0.68 KDM4E (0.53) KDM4EGPR3F12PLAUNCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2896613-B1 SULFONAMIDE COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2018-03-21 EP disclosed
EP-2896613-B1 SULFONAMIDE COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2018-03-21 EP disclosed
US-9540360-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-10 US disclosed
US-9540360-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-10 US disclosed
US-9540360-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-10 US disclosed
US-9487488-B2 Sulfonamide compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-11-08 US disclosed
US-9487488-B2 Sulfonamide compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-11-08 US disclosed
US-9487488-B2 Sulfonamide compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-11-08 US disclosed
CN-103443080-B There is the sulfonamide compounds of TRPM8 antagonistic activity 田边三菱制药株式会社 2016-10-12 CN disclosed
EP-2686302-B1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORP (JP) 2016-08-10 EP disclosed
EP-2896613-A1 SULFONAMIDE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-07-22 EP disclosed
EP-2896613-A1 SULFONAMIDE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-07-22 EP disclosed
US-8987445-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-24 US disclosed
US-8987445-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-24 US disclosed
US-8987445-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-24 US disclosed
WO-2014042238-A1 SULFONAMIDE COMPOUND 田辺三菱製薬株式会社 (JP) 2014-03-20 WO disclosed
EP-2686302-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY Mitsubishi Tanabe Pharma Corporation (JP) 2014-01-22 EP disclosed
US-20140005393-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY KALLYOPE, INC. 2014-01-02 US disclosed
WO-2012124825-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-09-20 WO disclosed
WO-2012124825-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005393-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY TRPM8, TRPM7, TRPM2 KDM4E 2496/4885GPR3 338/4885ACHE 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.